Transgenic Mice Can Express Mutant Human Coagulation Factor IX with Higher Level of Clotting Activity

Jing-Bin Yan,Shu Wang,Wen-Ying Huang,Yan-Ping Xiao,Zhao-Rui Ren,Shu-Zheng Huang,Yi-Tao Zeng
DOI: https://doi.org/10.1007/s10528-006-9034-1
2006-01-01
Biochemical Genetics
Abstract:To improve the available values of transgenic animals, we produced a mutant human coagulation factor IX minigene (including cDNA and intron I) with arginine at 338 changed to alanine (R338A-hFIX) by using a direct mutation technique. The R338A-hFIX minigene was then cloned into a plasmid carrying the goat beta-casein promoter to get a mammary gland-specific expression vector. The clotting activity in the supernatant of the transfected HC-11 cells increased to approximately three times more than that of wild-type hFIX. Nine transgenic mice (three females and six males) were produced, and the copy number of the foreign gene was very different, ranging from 1 to 43 in different lines. ELISA, Western blot, and clotting assay experiments showed that the transgenic mice could express R338A-hFIX, showing higher average levels of clotting activity than wild-type hFIX in the milk (103.76% vs. 49.95%). The highest concentration and clotting activity of hFIX reached 26 mu g/mL and 1287% in one founder (F-0-7), which was over 10 times higher than that in human plasma. Furthermore, RT-PCR, APTT assay, and histological analysis indicated that hFIX was expressed specifically in the mammary gland without affecting the intrinsic coagulation pathway and physiologic performance of the local tissue.
What problem does this paper attempt to address?